Summit Therapeutics Inc.
SMMT
$18.22
-$0.69-3.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -71.39% | 2,212.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -58.80% | 750.30% | |||
| Operating Income | 58.80% | -750.30% | |||
| Income Before Tax | 59.03% | -799.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 59.03% | -799.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 59.03% | -799.19% | |||
| EBIT | 58.80% | -750.30% | |||
| EBITDA | 58.80% | -750.57% | |||
| EPS Basic | 59.07% | -794.13% | |||
| Normalized Basic EPS | 59.06% | -793.25% | |||
| EPS Diluted | 59.07% | -746.44% | |||
| Normalized Diluted EPS | 59.06% | -793.25% | |||
| Average Basic Shares Outstanding | 0.11% | 0.61% | |||
| Average Diluted Shares Outstanding | 0.11% | 0.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||